That the prognostic role of PSAP was particularly strong in ERG-negative but was less prominent in ERG-positive cancers is in line with various earlier studies describing prognostic molecular features in prostate cancer that were either restricted to ERG-positive [44,45,46] or ERG-negative cancers [47,48]. This evidence concerns the gene PSAP and prostate cancer.